Methoxyamine and Temozolomide in Treating Patients With Advanced Solid Tumors

OBJECTIVES: * To determine the maximum tolerated dose of methoxyamine given in conjunction with temozolomide in patients with and without CNS disease. * To determine the dose limiting toxicities of the combination of methoxyamine and temozolomide in patients with and without CNS disease. * To determine the pharmacokinetics of these two agents when given alone or in combination, as well as the pharmacokinetic profile of methoxyamine after single one-hour IV administration. * To determine relative DNA damage, as single or double strand breaks by comet assay in blood mononuclear cells which will serve as a surrogate for tumor response to the drug combination. OUTLINE: This is a dose escalation study of methoxyamine. Patients receive oral temozolomide for 5 days every 28 days and methoxyamine IV over 1 hour every 28 days. Methoxyamine IV administration will follow, within 5 minutes, initial administration of TMZ on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Blood samples are collected periodically for correlative studies. Samples are analyzed for methoxyamine and temozolomide pharmacokinetics, apurinic/apyrimidinic sites, and DNA strand break determination by comet assay.